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AbstrAct:
The diagnosis, classification, and prognostication of patients with myelodysplastic 
syndromes (MDS) are usually based on clinical parameters, analysis of peripheral 
blood and bone marrow smears, and cytogenetic determinants. However, a 
thorough histologic and immunohistochemical examination of the bone marrow 
is  often  required  for  a  final  diagnosis  and  exact  classification  in  these  patients. 
Notably, histology and immunohistology may reveal dysplasia in megakaryocytes 
or other bone marrow lineages and/or the presence of clusters of CD34-positive 
precursor cells. In other cases, histology may reveal an unrelated or co-existing 
hematopoietic neoplasm, or may support the conclusion the patient is suffering 
from acute myeloid leukemia rather than MDS. Moreover, histologic investigations 
and immunohistology may reveal an increase in tryptase-positive cells, a 
coexisting systemic mastocytosis, or bone marrow fibrosis, which is of prognostic 
significance.  To  discuss  diagnostic  algorithms,  terminologies,  parameters,  and 
specific issues in the hematopathologic evaluation of MDS, a Working Conference 
involving a consortium of US and EU experts, was organized in June 2010. The 
outcomes of the conference and resulting recommendations provided by the 
faculty, are reported in this article. These guidelines should assist in the diagnosis, 
classification, and prognostication in MDS in daily practice as well as in clinical trials.Oncotarget 2010; 1:  483 - 496 484 www.impactjournals.com/oncotarget
INtrODUctION 
Myelodysplastic syndromes (MDS), also known 
as myelodysplastic neoplasms, are clonal disorders 
characterized by a maturation defect in myelopoietic 
progenitor cells, peripheral cytopenia(s), and clonal 
instability with an enhanced risk of transformation 
to secondary acute myeloid leukemia (sAML) [1-3]. 
MDS  are  classified  according  to  criteria  first  provided 
by the French-American-British (FAB) working group, 
and later integrated into the World Health Organization 
(WHO) proposal [4-6]. The WHO classification of MDS 
was updated in 2008 and provides robust criteria for the 
discrimination of MDS variants from each other [6]. In 
addition, minimal diagnostic criteria for MDS have been 
proposed [6,7]. These criteria allow discrimination of 
MDS from all other neoplastic or reactive disorders that 
can also produce cytopenia(s) or/and dysplasia. Diagnostic 
prerequisite-criteria for MDS include a) persistent 
significant  cytopenia(s),  b)  cytologic  or  cytogenetic 
evidence of myelodysplasia, and c) exclusion of all other 
conditions and disorders producing cytopenia(s) and/or 
dysplasia [7].
From a practical point of view, the diagnosis MDS 
is established in a step-wise procedure (Table 1). In a first 
step, minimal diagnostic criteria need to be fulfilled. Then, 
the subtype of MDS according to WHO criteria should be 
defined. Next, the patient is examined for individual risk 
factors and scores, in order to establish the overall risk 
profile, preferably by the international prognostic scoring 
system (IPSS) [8] and WHO-prognostic scoring system 
(WPSS) [9]. Finally, if applicable, treatment-scores are 
applied to define the optimal therapeutic approach (Table 
1).
In most patients with MDS, the bone marrow (BM) 
smear  reveals  marked  dysplasia  in  one  or  more  major 
hematopoietic lineage/s (erythroid, granulocytic, mega-
karyocytic)[10,11]. With regard to megakaryopoiesis, a 
frequent problem in MDS is that megakaryocyte numbers 
in BM smears may be rather low. Monocytosis or/and an 
increase in blast cells may also be detected in BM smears 
[10,11]. Typical blood count abnormalities recorded in 
MDS include macrocytic anemia, bi- or pancytopenia, 
and signs of dysplasia such as abnormal hypogranulated 
or/and hypolobated neutrophils (e.g. Pseudo-Pelger-Huet 
cells). In most patients, a provisional diagnosis of MDS can 
be established on examination of blood and BM smears. 
In other patients, no prominent dysplasia is found but an 
abnormal karyotype is detected, leading to the conclusion 
the patient may suffer from MDS [7]. However, there are 
also patients with normal karyotype in whom it is difficult 
to define whether cytopenia or dysplasia would indeed 
result from an underlying MDS, a prephase of MDS, 
or  from  another  hematologic  or  even  non-hematologic 
disease [7]. In other patients, it is difficult to discriminate 
between advanced MDS and AML, or a myelodysplastic/ 
myeloproliferative overlap disease (MDS/MPN).
In  all  these  instances,  histological  and 
immunohistochemical  examination  of  BM  biopsies,  a 
diagnostic approach which was often underestimated 
in the past, contributes essentially to the diagnosis, 
classification,  and  prognostication  of  (suspected/
provisional) MDS [7,12,13]. In order to discuss current 
standards  in  the  evaluation  of  MDS  by  histology  and 
immunohistochemistry, a Working Conference was 
organized in June 2010. The participating faculty 
discussed  current  and  novel  diagnostic  procedures  and 
markers, related criteria, and diagnostic algorithms. The 
outcome was formulated into consensus statements. The 
level  of  consensus  was  defined  as  percent  agreement 
(percent of faculty members agreed). A summary of 
consensus statements and related recommendations are 
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tables 
 
Table 1 
 
Step-wise approach in the diagnosis, prognostication, and treatment in MDS 
-------------------------------------------------------------------------------------------------------- 
1. Minimal Diagnostic Criteria      Establish the Diagnosis MDS 
 
2. FAB and WHO Classification     Establish the MDS Subtype/Variant  
 
3. IPSS, WPSS and other Scores     Establish the Risk of Transformation (AML) 
 
4. Patient-related Risk Factors*      Estimate (AML-free) Survival Times 
 
5. Therapy-related Scores          Establish the Treatment Plan 
 
6. Response Criteria              Determine Treatment Responses 
-------------------------------------------------------------------------------------------------------- 
MDS, myelodysplastic syndromes; FAB, French-American-British working group; 
WHO,  world  health  organization;  IPSS,  international  prognostic  scoring  system; 
WPSS, WHO-adapted prognostic scoring system. *Patient-related risk factors include 
variables not covered by the IPSS/WPSS, such as age or comorbidity.  
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presented in this article.
bAsIc rEcOMMENDAtIONs
The faculty agreed 100% that it is essential for 
the  pathologist  to  receive  BM  samples  together  with 
relevant clinical information and laboratory parameters, 
a complete blood count (CBC) with differential count as 
well as unstained BM and peripheral blood (PB) smears, 
in order to establish the correct diagnosis. The BM biopsy 
specimen (iliac crest) should be of adequate length (≥2 
cm).  Specimens  should  be  fixed  in  neutral-buffered 
formalin,  decalcified  in  edetic  acid,  and  embedded  in 
paraffin-wax  [12].  Alternative  fixation  and  embedding 
techniques are acceptable provided that the quality of the 
morphologic stain and the section immunoreactivity are 
both adequate. Standard routine stains include H&E and/
or Giemsa, and Gömöri´s silver stain for the evaluation 
of  fibrosis  [12,14].  Special  stain  for  naphtol  AS-D 
chloroacetate esterase (CAE) is helpful in determining 
the erythroid:myeloid ratio, and may provide a first hint 
for the presence of a CAE-negative (lymphoid or blast) 
infiltrate or/and granulocyte dysplasia. The BM cellularity 
is reported as percentage of section-area according to the 
standard proposed by Tuzuner and Bennett [15]. A widely 
used approach is to classify the estimated BM cellularity 
as ´normocellular´, ´hypocellular´, or ´hypercellular´. 
Such estimate should be based on age-adapted normal 
values  proposed  for  the  groups  20-30  years  (60-70% 
cellularity), 40-60 years (40-50%), and ≥70 years (30-
40%) [16]. In each case, a Prussian blue stain (iron stain) 
should be performed on a BM smear.
LINEAGE AssEssMENt bY IMMUNOHIs 
tOcHEMIstrY AND rEcOMMENDED 
MArKErs
The  application  of  immunohistochemical  (IHC) 
markers is recommended in all patients with (suspected) 
MDS [7,12,14]. Because of subclone-formation and 
phenotypic diversity, it may sometimes be necessary to 
apply multiple markers for one lineage (cell type) even in 
the same patient. The participants agreed that all major BM 
lineages should be examined by immunohistochemistry 
in  (suspected/provisional)  MDS.  The  minimal  panel 
recommended for all patients includes CD34 (progenitor/
precursor cells), CD117/KIT (progenitor/precursor cells, 
mast cells), tryptase (mast cells, immature basophils), 
C B
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Figure 1: Application of lineage-associated immunohistochemical markers in MDs. Bone marrow sections obtained from patients 
with MDS stained with antibodies against CD34 (A, B), CD42b (C), tryptase (D), 2D7 (E), and eosinophil major basic protein, EMBP (F). The 
CD34 stain is useful for detection of immature precursor cells (blast cells) in patients with RAEB (A). Megakaryocytes and megakaryoblasts 
may also stain positive for CD34 in MDS (B). A preferred marker of the megakaryocyte lineage is, among other, CD42b (C). The tryptase stain 
may reveal an increase in mast cells (D), whereas 2D7 (E) is specific for basophils, and EMBP (F) is useful for the visualization of eosinophils 
in patients with MDS.Oncotarget 2010; 1:  483 - 496 486 www.impactjournals.com/oncotarget
one megakaryocyte marker (CD61 or CD42b), CD20 
(B-lineage), CD3 (T cells), and glycophorin-A or -C (Table 
2).  Additional  (lineage-specific)  markers  are  applied 
depending on initial staining results and further clinical 
and laboratory parameters. Such additional markers 
are essential when the diagnosis MDS is in question or 
another  co-existing  neoplasm  is  suspected.  Sometimes, 
the application of an antibody against myeloperoxidase 
(MPO), CD25, CD33, or lysozyme is helpful [12]. Using 
the minimal marker-panel proposed, the pathologist can 
also study endothelial cells (CD34+/CD31+) and may 
report on microvessel density [17].
The CD34 stain is useful for the detection of clusters 
and/or aggregates of immature myeloid cells which should 
be reported if present [18,19]. In instances where blast 
cells are CD34-negative cells, KIT is recommended as an 
alternative (additional) marker [7,12]. However, because 
KIT is also expressed by a proportion of proerythroblasts 
[20], evaluation may be difficult in erythroid-rich cases. 
The faculty agreed that it is essential to report on the 
estimated percentage of CD34+ cells (percent of all 
nucleated cells) in each case of (suspected or overt) MDS. 
The faculty also agreed that any multifocal accumulation 
(abnormal clustering) of CD34+ cells (Figure 1A) must be 
regarded abnormal and potentially indicative of an MDS. 
Without immunostaining, i.e. by morphology alone, it 
is quite difficult to identify an abnormal localization of 
immature precursor cells (ALIP) [21], in particular when 
there is sub-optimal fixation of the trephine. An easier and 
probably more accurate feature to describe and record in 
(suspected/provisional) MDS is the ´Abnormal Multifocal 
Accumulation (clustering) of CD34+ precursor cells´ 
(AMA-CD34) (Figure 1A), which should thus replace 
the  reporting  on  ALIP  [7,12]. Nevertheless,  histologic 
blast cell recognition remains important because 
subpopulations or (rarely) the entire population of blasts 
may be CD34-negative cells. If an increase of blast cells 
can neither be documented by histomorphology nor in 
bone marrow smears, the phrasing should change to the 
more appropriate term of ´CD34+ progenitor/precursor 
cells´. 
Megakaryocyte-reactive antibodies are useful for the 
visualization  of  normal  and  abnormal  megakaryocytes, 
and their (abnormal) accumulation in the BM [12,14]. 
Both small-sized megakaryocytes (dwarf forms including 
micromegakaryocytes) and megakaryoblasts can be 
identified using this approach (Figure 1B and 1C). Notably, 
in almost all patients with MDS, megakaryocytes show 
both atypical cytologic features and abnormal distribution 
[7,12]. The faculty agreed that CD61 and CD42b can be 
considered as ´standard megakaryocyte markers´ in MDS 
(Table 2). The linker for activation of T cells (LAT), van 
Willebrand factor (vWF, factor VIII antigen), CD25, and 
CD31 are also expressed in megakaryocytes. Furthermore, 
the CD34 antigen may be detectable in (immature) 
megakaryocytes and megakaryoblasts in MDS (Figure 
1B and 1C). However, CD34-expression is not a specific 
feature of MDS-megakaryocytes. On the other hand, most 
megakaryocytes in the normal/reactive BM usually are 
CD34-negative, so that a clear-cut expression of CD34 
in  a  majority  of  megakaryocytes  must  be  regarded  as 
phenotypic aberrancy supporting the conclusion the 
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Table 2 
 
Immunohistochemical markers recommended for the evaluation of MDS 
------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Marker                      Cell                    Recommended by Faculty 
CD        Antigen           Type(s)                 (Consensus Level %)*       Value/Impact in MDS                
------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
CD34      HPCA-1          Progenitor cells,             100%              RAEB-2 vs AML, hypoplastic MDS,      
                           endothelial cells                                microvessel density, megakaryoblasts      
CD117     KIT/SCFR        Progenitor cells, mast cells,    90%               Mastocytosis, SM-MDS,   
                          immature erythroblasts                          CD34-negative clones 
CD31      PECAM-1         Megakaryocytes,            <50%              Abnormal megakaryocytes, dwarf forms 
                          endothelial cells                                Microvessel density 
CD42      GPIX            Megakaryocytes             65%               Abnormal megakaryocytes, dwarf forms 
CD61      VNRß            Megakaryocytes            90%               Abnormal megakaryocytes, dwarf forms 
n.c.        Glycophorin-A/C    Erythroid cells              65%               Erythroid hyperplasia  , AML M6 vs MDS 
n.c.        Myeloperoxidase     Myeloid cells              70%               Neutrophilic cells, maturation defect     
n.c.        Tryptase          Mast cells, immature         85%               Mastocytosis, SM-MDS       
                           basophils                                    Basophilia MDS vs MPN 
CD14      LPSRr            Monocytes, subset           95%               CMML vs MDS 
                           of macrophages 
CD68R     PGM1            Macrophages, histio-           55%               CMML vs MDS 
                          cytes, monocytes,  
                          mast cells 
CD3       TCR             T cells                    85%               T cell neoplasm s 
CD20      B1              B cells                    85%               B cell neoplasms 
CD25       IL2Ralpha         Megakaryocytes, histiocytes,   85%               Abnormal megakaryocytes             
                          T cells, atypical mast cells                       SM-MDS 
2D7        2D7-antigen        Basophils                 90%               Basophilia, basophilic leukemia      
------------------------------------------------------------------------------------------------------------------------------------------------------------------ 
table 2: Immunohistochemical markers recommended for the evaluation of MDsOncotarget 2010; 1:  483 - 496 487 www.impactjournals.com/oncotarget
patient suffers from a myeloid neoplasm such as MDS.
The tryptase stain is useful to detect loosely scattered 
mast cells which are increased in a majority of patients 
with MDS and may show a spindle-shape morphology 
(Figure 1D) [12]. Serum tryptase levels are also elevated 
in a group of patients with MDS [22]. If mast cells form 
compact clusters in the BM and/or express CD25, or the 
serum tryptase level is markedly elevated, it is appropriate 
to perform KIT mutation analysis [7,12]. In such cases, 
a  coexisting  (occult)  systemic  mastocytosis  is  detected 
quite frequently.
So far, only very few immunohistochemical markers 
sufficient for the evaluation of basophils and eosinophils 
in BM sections are available. For basophil evaluation and 
counting, 2D7 and BB1 (basogranulin) are recommended 
antigens (Figure 1E) [23,24] while eosinophils can be 
visualized  using  an  antibody  against  eosinophil  major 
basic  protein  (EMBP)  (Figure  1F).  Whereas  a  slight 
or moderate increase of eosinophils is often seen in 
reactive and neoplastic disease states, constant basophilia 
is uncommon in reactive states and thus regarded as a 
potential indicator for the presence of a myeloid neoplasm. 
However,  no  robust  studies  employing  basophil  or 
eosinophil IHC markers in MDS have been conducted so 
far. The faculty agreed that such investigations should be 
performed in order to examine the utility of such markers 
and the impact of BM eosinophilia and basophilia in MDS. 
If BM or blood eosinophilia is substantial in MDS, the BM 
should be examined for the presence of rearrangements 
involving PDGFR and FGFR genes.
IMPAct OF HIstOPAtHOLOGIc 
PArAMEtErs IN tHE DIAGNOsIs OF 
MDs
The diagnosis of MDS is primarily based on the 
presence of persistent (of at least 6 months duration) 
cytopenia(s), cytomorphologic dysplasia in one or 
more  major  BM  lineages  (erythroid,  granulocytic, 
megakaryocytic), and exclusion of other potential disorders 
that can produce cytopenia and dysplasia [7]. To address 
these criteria and thus establish the exact diagnosis, it is 
essential to examine a representative BM biopsy section 
by histology and immunohistochemistry. First, the BM 
histology may reveal a myeloid neoplasm other than MDS, 
or MDS with a coexisting neoplasm (hematopoietic or 
non hematopoietic). Likewise, in patients with provisional 
RAEB-2, the BM biopsy may reveal a final diagnosis of 
AML (e.g. by demonstrating sheets of CD34+ cells). In 
other cases of (provisional) MDS, a co-existing systemic 
mastocytosis (SM) will be detected, leading to the final 
diagnosis  of  SM-MDS  [12].  Another  example  is  the 
discrimination between aplastic anemia, hypoplastic 
MDS, and hypoplastic AML [3]. Again, the final diagnosis 
in these patients cannot be established without a thorough 
investigation of BM sections. Finally, the BM histology 
may reveal a myeloproliferative neoplasm or an MDS/
MPN overlap disease, which can be accompanied by the 
JAK2 mutation V617F [25].
After having excluded other (differential) diagnoses 
in a cytopenic patient, the pathologist will examine the 
BM for signs of dysplasia in detail. Whereas dysplasia of 
erythroid cells and neutrophils is examined preferentially 
in BM and PB smears, megakaryocyte dysplasia can often 
be assessed more accurately in BM sections [3,7,12]. This 
is often essential, especially when BM smears contain only 
a few megakaryocytes. The faculty agreed that dysplasia 
should count as an MDS-specific criterion, when ≥10% of 
cells in a given lineage show clear signs of dysplasia, as 
has been proposed by the WHO and other working groups 
[5,7]. However, as mentioned above signs of dysplasia 
in one or even more lineages may also be recorded in a 
variety of other hematopoietic and even non-neoplastic 
conditions,  such  as  vitamine  B12  or  folate  deficiency, 
viral infections, or chronic inflammation. 
IMPAct OF HIstOPAtHOLOGY IN tHE 
cLAssIFIcAtION OF MDs
a. Evaluation of megakaryopoiesis and 
megakaryocyte dysplasia
As mentioned above it may be essential to confirm 
or reveal megakaryocyte dysplasia in the BM histology. 
Thus, the diagnosis of multi-lineage dysplasia, a major 
diagnostic determinant in the WHO classification [5] often 
depends on a thorough assessment of megakaryocytes in 
BM sections because BM smears often contain only low 
numbers of megakaryocytes in MDS. The presence of dwarf 
megakaryocyte forms (including micromegakaryocytes) 
and abnormalities in their distribution as frequently 
seen in MDS can be best established by examining BM 
sections immunostained with one or more megakaryocyte 
marker(s) such as CD61, CD42b, or CD31 (Figure 1C) 
[12,14].  As  previously  mentioned,  aberrant  expression 
of CD34 in megakaryocytes can be seen in MDS (Figure 
1D). However, this phenomenon is neither specific for 
MDS nor related to a specific subtype of MDS. Small 
megakaryocytes with markedly hypolobated nuclei 
(´mononuclear megakaryocytes´) are typically found 
in patients with the 5q- anomaly. However, there is no 
absolute correlation between a particular megakaryocyte-
morphology and a certain cytogenetic abnormality in 
MDS.
b. Evaluation of cD34+ cells and delineation 
between low risk MDs and high risk MDs
An important diagnostic approach in MDS is Oncotarget 2010; 1:  483 - 496 488 www.impactjournals.com/oncotarget
the  evaluation  of  CD34+  progenitor/precursor  cells  in 
BM histologic sections. This approach is helpful (often 
essential) for the delineation between low risk MDS (RA, 
RARS, RCMD) and high risk MDS (RAEB-1, RAEB-2) 
[18,19]. In each case, the estimated percentage of CD34+ 
cells (called blast cells when BM smears confirm blast cell 
morphology) should be reported. Abnormal multifocal 
accumulation of CD34+ cells (AMA-CD34) is only seen 
in patients with high risk MDS [3,7,12]. In case of CD34-
negative progenitor cells (blasts), KIT/CD117 can also be 
employed as alternative marker antigen. However, KIT is 
also expressed on other BM cells including mast cells and 
a subset of (immature) erythroblasts [20].
c. Hypoplastic MDs (MDs-hypo)
Another proposed subtype of MDS that can only be 
diagnosed by histology is hypoplastic MDS [3,12]. The 
faculty agreed that this subtype should be recognized 
as a separate variant of MDS and should be defined by 
robust criteria. In fact, MDS should be called hypoplastic 
MDS when a) minimal diagnostic criteria for MDS [7] 
are fulfilled, b) the BM section is hypocellular compared 
to age-matched normal BM cellularity [16], and c) causes 
and  therapies  producing  transient  cytopenia  have  been 
excluded. Cases of therapy-related MDS can also present 
with hypocellular marrows. Sometimes, it may be difficult 
to differentiate between hypoplastic MDS and hypoplastic 
AML [3,13]. Histologic or immunohistochemical 
identification  of  immature  precursor/blast  cells  (by 
antibodies  against  CD34  and  KIT)  is  essential  in 
identifying  these  cases,  and  to  established  the  final 
diagnosis of hypoplastic MDS or hypoplastic AML 
(Figure 2A) [12,26].
d. MDS with bone marrow fibrosis (MDS-F)
Another prognostic variable in MDS is BM fibrosis 
[27-29].  The  degree  of  fibrosis  should  be  assessed 
according to the European Consensus Grading System also 
known as EURO-Score[16] and should be reported in all 
MDS patients. The presence of BM fibrosis EURO-Score 
grade II or grade III is required to call the disease MDS-F 
(Figure 2B). The faculty then discussed whether MDS 
patients presenting with such marked BM fibrosis should 
be regarded as a separate category of MDS. However, 
after  intensive  discussion,  the  faculty  agreed  by  80% 
that the term MDS-F would be appropriate, but MDS-F 
should  not  be  regarded  as  a  separate  variant  of  MDS. 
Rather,  in  each  MDS  variant  and  subvariant,  the  final 
diagnosis should include the appendix ´-F´ when fibrosis 
of ´grade II´ or ´grade III´ was recorded (e.g. RCMD-F, 
RAEB-F) (Figure 2B). The faculty also agreed that the 
presence of fibrosis (-F) in MDS should be included in 
the  final  pathology  report  in  each  case  because  of  its 
well known prognostic significance [27-29]. Moreover, 
in these patients, the clinician and the pathologist have 
to look for (additional) signs of myeloproliferation, i.e. 
A B C
Figure 2: Diagnostic potential of histomorphological features in MDs and delineation of MDs subtypes. A: 
Immunohistochemistry reveals an increase in CD34+ precursor cells in a patient with hypoplastic MDS. Note focal clustering of CD34+ 
precursor (blast) cells in the bone marrow section. B: The fibrotic form of MDS (MDS-F) as evidenced by Gömöri´s silver stain (grade III). 
C: MDS associated with systemic mastcytosis (SM-MDS) as evidenced by staining the bone marrow section for mast cell tryptase. Note the 
compact infiltrate of spindle shaped tryptase-positive mast cells in this patient.Oncotarget 2010; 1:  483 - 496 489 www.impactjournals.com/oncotarget
increased spleen size, leukocytosis with left shift, marked 
eosinophilia and/or basophilia, marked thrombocytosis, 
histologic  features  of  an  MPN,  JAK2 V617F, or/and 
a  markedly  elevated  serum  tryptase  level  (>100  ng/
ml) [7,12,25,30]. When two or more of these additional 
features are recorded, the diagnosis of MDS is in question, 
and the more likely final diagnosis may be an MDS/MPN 
overlap  disease,  an  associated/pre-existing  MPN,  mast 
cell disease (mastocytosis), or even an unusual MPN with 
BM dysplasia (Table 3). In other words, MDS-F has to be 
delineated from various differential diagnoses including 
primary myelofibrosis (PMF). The faculty agreed that the 
term ´myelofibrosis´ should be avoided in patients with 
MDS-F.
e. MDs associated with systemic mastocytosis 
(sM-MDs)
38 
 
 
Table 3 
 
Impact of Myeloproliferative Features recorded in MDS & Differential Diagnoses 
-------------------------------------------------------------------------------------------------------- 
Feature in Overlap-Clusters A-D*          Examples of Differential Diagnoses** 
-------------------------------------------------------------------------------------------------------- 
A: MEGA/FIBRO-Cluster 
Bone Marrow (BM) Fibrosis  II or III***    a) 5q- syndrome or RARS-T  
Thrombocytosis >600,000/µL            b) MDS/MPN Overlap Disease  
Palpable Splenomegaly                 c) MPN/PMF with BM dysplasia 
Abnormal clustering of megakaryocytes 
Markedly elevated CFU-GM 
JAK2 V617F 
 
B: EO/BASO-Cluster 
Leukocytosis with Neutrophilia           a) MDS-U, MDS-eo 
Marked Left Shift in BM or blood smears     b) MDS/MPN Overlap Disease 
Marked Eosinophilia and/or Basophilia      c) Eosinophilic Leukemia or  
PDGFRA/B mutant                        Basophilic Leukemia with 
FGFR mutant                          BM dysplasia         
 
C: MAST CELL-Cluster          
Atypical CD25+ Mast Cells               a) MDS with increase in mast cells 
Markedly increased Serum Tryptase         b) Myelomastocytic Overlap Disease 
Urticaria Pigmentosa                       or SM-MDS 
KIT D816V                          d) SM with BM dysplasia, SSM 
 
D: MONO-Cluster 
BM or blood Monocytosis (>1,000/µL)      a) MDS with mild monocytosis 
Marked increase in CD14+ cells           b) CMML (Overlap) 
Autonomous CFU-GM growth            c) Monoblastic Leukemia (AML) 
-------------------------------------------------------------------------------------------------------- 
*Features are clustered according to potential differential diagnoses and involvement 
of certain hematopoietic lineages. When 2 or more of the features from one cluster are 
detected, the diagnosis MDS is in question and the more likely diagnosis is an overlap 
or another unrelated malignancy. **Each 3 examples of a typical differential diagnosis 
are depicted: a) MDS-type disease,  b)  MDS/X  overlap,  and  c)  another  unrelated 
disease = without coexisting frank MDS. ***Fibrosis should be graded according to 
the Euro-Score.
15 MDS, myelodysplastic syndromes; RARS-T, refractory anemia with 
ring sideroblasts and thrombocytosis; MDS/MPN, myeldysplastic/myeloproliferative 
overlap  disorder;  CFU-GM, granulocyte/macrophage colony-forming unit; MDS-U, 
unclassifiable MDS; MDS-eo,  MDS  with  marked  eosinophilia;  PDGFR,  platelet 
derived growth factor; SM, systemic mastocytosis; CMML, chronic myelomonocytic 
leukemia; AML, acute myeloid leukemia, SSM, smouldering SM.  
table 3: Impact of Myeloproliferative Features recorded in MDs & Differential DiagnosesOncotarget 2010; 1:  483 - 496 490 www.impactjournals.com/oncotarget
In a very small group of patients with MDS, a co-
existing SM is detected (Figure 2C) [12,31-33]. In most of 
these patients, an increased serum tryptase level (>20 ng/
ml) and the KIT mutation D816V are found, and several 
of them present with typical skin lesions of the urticaria 
pigmentosa  type.  If  this  is  not  the  case,  isolated  bone 
marrow mastocytosis (BMM) may be diagnosed [34,35]. 
The detection of KIT D816V is helpful in these cases, 
as the mutant is rarely if ever detectable in MDS cases 
without SM. It is noteworthy that KIT mutation analysis 
can not only be performed in BM aspirates but also by 
using paraffin-embedded material.
The  diagnosis  SM-MDS  is  a  provisional  one 
because both the SM component and MDS components 
of the disease need to be subclassified according to WHO 
criteria [34,35]. An important aspect is that patients with 
advanced  SM  including  smouldering  SM  (SSM)  and 
aggressive  SM,  often  present  with  cytopenia  and  mild 
dysplasia [30,34,35]. Therefore, it is of importance to 
confirm  the  diagnosis  MDS  in  these  patients  by  using 
robust histologic, cytomorphologic, and cytogenetic 
parameters. Relatively strong reliable indications for an 
MDS include a macrocytic transfusion-dependent anemia, 
an increase in myeloblasts (CD34+ cells), and/or the 
presence of an MDS-related cytogenetic abnormality. The 
prognosis in patients with SM-MDS is variable. In those 
in whom BMM is diagnosed (BMM-MDS), the prognosis 
is usually defined by the MDS component of the disease 
[33]. However, in patients with ASM-MDS or MCL-MDS, 
the mast cell disease subclone may be the prognostically 
(more) important disease-component [31-33].
f. Erythroid-predominant MDs (MDs-Ery)
In a small group of patients with advanced MDS, 
erythropoiesis is clearly predominant, so that the question 
arises whether the patient is suffering from MDS or 
from erythroleukemia (formerly termed AML-M6) [36]. 
The classical definition of erythroleukemia relates to the 
percentage of blast cells in the non-erythroid compartment 
of the BM (≥20% by WHO criteria) [37-39]. The faculty 
discussed these criteria, and specifically asked whether 
the percentage of blasts among all nucleated BM cells 
should also count as criterion of AML M6 in these 
patients. The faculty agreed that it may be appropriate to 
report on marked erythroid hyperplasia (>50% erythroid 
cells in the BM) in all cases, and to regard cases with such 
erythroid predominance as a provisional subcategory of 
MDS (proposed: erythroid-predominant MDS = MDS-
Ery) when criteria for AML are not (yet) fulfilled. The 
faculty  also  agreed  that  the  traditional  definition  of 
erythroleukemia (M6) should still be recommended as a 
global standard, but that it may be appropriate to start a 
discussion to modify this definition in the future, and to 
regard only those cases as frank AML M6 in whom blast 
cells account for ≥20% of all nucleated BM cells (instead 
of ≥20% of all non-erythroid cells). All other cases with 
erythroid predominance but <20% blasts (of all nucleated 
BM cells) would then be called MDS-Ery (e.g. RAEB-
1-Ery). In cases of MDS-Ery, the blast cell percentage 
obtained from counting non-erythroid marrow cells, 
represents a prognostically significant variable [36].
tHE OVErLAP DIsOrDErs
Three overlap conditions were discussed in detail 
by the faculty. Each of these disorders is characterized by 
massive expansion of more or less dysplastic cells in a 
distinct hematopoietic cell lineage. 
a. chronic Myelomonocytic Leukemia (cMML)
Traditionally,  CMML  is  defined  by  absolute 
monocytosis  (>1000/µL),  myeloid  dysplasia,  and 
exclusion  of AML  [25,40-43].  The  faculty  agreed  that 
an absolute monocytosis is a robust criterion of CMML. 
However,  in  patients  with  high  leukocyte  counts, 
the percentage of monocytes may be a more reliable 
(robust) parameter. Therefore, the faculty recommends 
that in forthcoming classification proposals, the relative 
monocyte count (e.g. >10%) should be considered as an 
additional criterion, especially when leukocyte counts 
are  very  high.  The  WHO  classification  discriminates 
CMML-1 (less than 10% blasts in BM) from CMML-
2  (10-19%  blasts). The  faculty  agreed  that  a  thorough 
histomorphological  and  immunohistochemical  (or  flow 
cytometric)  investigation  of  BM  cells  is  essential  for 
the diagnosis of CMML (recommended marker: CD14)
[43] and delineation between CMML-1 and CMML-2 
(recommended marker: CD34), which may be difficult 
as monoblasts or promonocytes often lack CD34 [41,42]. 
Because of their frequent CD34-negativity and the difficult 
histologic identification of promonocytes, the separation of 
CMML-2 from acute myelomonocytic or acute monocytic 
leukemia may sometimes be difficult, particularly in the 
absence of flow cytometry and/or cytogenetics. Notably, 
in these patients, a thorough examination of a good quality 
BM smear as well as flow cytometry may be helpful to 
reach the final diagnosis.
A detailed cytogenetic and molecular analysis is 
required in all patients with CMML. The panel of markers 
to be applied in these patients depends on involvement of 
additional lineages (apart from monocytes): for example, 
in those with marked (PB or BM) eosinophilia, neoplastic 
cells should be screened for the presence of PDGFR- or 
FGFR rearrangements. When mast cells are reported to be 
abnormal and/or increased in number, PB and BM cells 
should be examined for the presence of KIT D816V. In 
mutant-positive cases, the tryptase-stain usually reveals 
(an  otherwise  overlooked  or  occult)  co-existing  BM 
mastocytosis  (BMM).  In  other  patients,  mutations  in Oncotarget 2010; 1:  483 - 496 491 www.impactjournals.com/oncotarget
RAS, JAK2, TET2, CBL, or RUNX1 are found [44,45]. 
Sometimes, the monocyte compartment expands or even 
shrinks (spontaneously) over time, so that the diagnosis 
may change (e.g. from RA to CMML). An increase in 
CD34+ cells is usually followed by evolution to AML.
b. Myelomastocytic Leukemia (MML)
This overlap disease is an extremely rare condition 
defined by an advanced myeloid neoplasm and prominent 
secondary  expansion  of  clonal  mast  cells  [31,46-48]. 
Major  differential  diagnoses  are  (primary)  mast  cell 
leukemia (MCL), mastocytosis with associated MDS 
(SM-MDS), and basophilic leukemia [31,48]. MML is 
defined by a) an advanced MDS (or another advanced 
myeloid neoplasm), b) at least 10% atypical mast cells 
in BM or PB smears, and c) exclusion of a primary mast 
cell disease, i.e. SM criteria are not fulfilled in these cases 
[31,46]. In contrast to MCL and SM-MDS, no focal mast 
cell  aggregates  are  present;  only  a  diffuse  infiltration 
of the BM by atypical immature mast cells is found in 
MML [31,46]. In addition, no KIT mutation at codon 816 
is found in MML, and neoplastic mast cells usually are 
CD25-negative cells.46 MML can also be discriminated 
from basophilic leukemia by immuno-phenotyping, as 
mast cells are KIT+/CD34-/2D7- cells, whereas basophils 
are KIT-/CD34-/2D7+ cells.
c.  MDS/MPN  overlap  disorders  with  basophilia  and/or 
eosinophilia
Demonstration of prominent basophilia and/or 
eosinophilia in the PB and/or the BM in an MDS patient 
is an important diagnostic checkpoint [49-51]. In these 
patients  it  is  appropriate  to  exclude  or  reveal  certain 
myeloid neoplasms defined by distinct cytogenetic and/
or molecular markers. In rare cases, an accelerated phase 
of  Ph+  CML,  advanced  mast  cell  neoplasm,  or  8p11 
syndrome  involving  the  FGFR are detectable [48-50]. 
More frequently, myeloid neoplasms with abnormalities 
in the PDGFRA- or PDGFRB genes, are detected[49-51], 
which is of clinical importance, as most of these patients 
respond to imatinib [52,53]. In some of these cases, BM 
dysplasia is found, so that it is justified to diagnose an 
MDS/MPN  overlap  disease.  In  the  majority  of  cases, 
however, no prominent BM dysplasia is recorded.
IMPAct OF HIstOPAtHOLOGY IN tHE 
PrOGNOstIcAtION OF MDs
There are a number of important prognostic 
parameters that should be addressed and reported by 
the hematopathologist when evaluating BM sections in 
MDS patients. Most important prognostic histopathologic 
variables in MDS are the presence of AMA-CD34 (increase 
in  CD34+  cells),  marked  BM  fibrosis,  and  an  overt 
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Figure 3: Evaluation of cD34+ cells in the MDs marrow by tissue-FAXs. A. Percentage of CD34+ cells in the bone marrow of 
patients with acute myeloid leukemia (AML), MDS subtype RAEB, and MDS subtype RARS. The percentage of CD34+ cells was determined 
(estimated) in CD34-stained bone marrow sections by microscopy (black bars) as well as by TissueFAXS using HistoFAXS software (grey bars) 
in blinded fashion. As visible, there was an excellent correlation when comparing the two techniques of quantification of CD34+ progenitor 
cells. B:.Correlation of CD34+ cell counts in all patients (correlation coefficient R=0.99).Oncotarget 2010; 1:  483 - 496 492 www.impactjournals.com/oncotarget
MDS/MPD overlap disease, including myelomastocytic 
transformation.
AbErrANt PHENOtYPEs IN MDs: rOLE 
OF bM IMMUNOHIstOcHEMIstrY, 
NOVEL tEcHNOLOGIEs, AND 
cOMPArIsON tO FLOW cYtOMEtrY
Compared to flow cytometry, only very little is known 
about aberrant antigenic expression by immunohistology 
in MDS. As mentioned before, expression of CD34 in 
megakaryocytes can occur in MDS, but is not a specific 
feature. Compared to normal (mature) blood basophils, 
BM basophils in MDS often are immature cells and may 
therefore synthesize and express substantial amounts of 
tryptase [54]. Aberrant expression of CD25 in BM mast 
cells has  also  been described. However,  none  of  these 
aberrant  immunohistochemical  features  are  specific  for 
MDS. Further examples are a loss of CD34 in myeloblasts 
or loss of MPO in more mature myeloid cells in the BM 
in MDS. Again, these features are not specific for MDS. 
The faculty agreed that it may be important to confirm 
aberrant markers discovered by flow cytometry [55] in 
MDS patients by an immunohistochemistry approach in 
BM sections in these patients. However, in contrast to 
flow cytometry, immunohistochemical parameters cannot 
usually be assessed by computerized multi-color-staining. 
One such future technique that may be helpful to overcome 
this problem may be tissue FAXS [56]. The faculty agreed 
that novel technologies to better quantify immunoreactivity 
and to detect aberrant immunophenotypes of BM lineages 
in MDS would be beneficial and that this should be further 
investigated in preclinical research programs. In one such 
pilot project presented by a member of the faculty, tissue 
FAXS  allowed  an  accurate  assessment  of  the  numbers 
of CD34+ BM cells (Figure 3). There are a number of 
markers  that  are  expressed  aberrantly  and  should  be 
examined in BM cells in MDS in future projects. Most 
interesting markers to be examined in CD34+ blast cells 
may be HLA-DR, CD7, and CD45 [55]. In fact, these 
markers clearly show aberrant expression in CD34+ blast 
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Table 4 
 
Comparison of Criteria Defining  Idiopathic  Cytopenia  of  Unknown  Significance 
(ICUS) and Idiopathic Dysplasia of Unknown Significance (IDUS) 
-------------------------------------------------------------------------------------------------------- 
Diagnosis/ 
Condition         Defining Criteria                 Additional Features 
-------------------------------------------------------------------------------------------------------- 
ICUS           Constant marked cytopenia*        elderly patients 
              No MDS detected by criteria        EPO levels low 
              No dysplasia/karyotype**           FISH may reveal 
              No MDS-Co-Criteria***          a small MDS-clone 
               No other disease as a primary       in the bone marrow 
              reason for cytopenia found                  
 
IDUS          No constant marked cytopenia*     often young patients 
               No MDS found by criteria         usually detected in 
               Dysplasia and/or karyotype**       a routine blood test 
              No other disease as reason for      (e.g. ´Pelger forms´ or 
              Dysplasia/karyotype detected        macrocytosis) 
-------------------------------------------------------------------------------------------------------- 
MDS,  myelodysplastic  syndromes;  EPO,  erythropoietin;  FISH,  fluorescence  in  situ 
hybridization; BM, bone marrow. *constant: at least 6 months: marked: hemoglobin 
<10 g/dL, neutrophils <1,000/µL blood, platelets <100,000/µL; **diagnostic 
dysplasia: ≥10% of cells in one or more major hematopoietic lineages; karyotypes 
typically found in MDS; it is important to note that the diagnosis IDUS should only be 
established when clear signs of dysplasia in at least two hematopoietic lineages are 
detectable. ***if one or more co-criteria are found in suspected MDS, the condition 
should be termed “highly suspicious for MDS”.  
  Table 4: Comparison of Criteria Defining Idiopathic Cytopenia of Unknown Significance (ICUS) and Idiopathic Dysplasia 
of Unknown Significance (IDUS)Oncotarget 2010; 1:  483 - 496 493 www.impactjournals.com/oncotarget
cells in flow cytometry studies.
IDIOPAtHIc cYtOPENIA (IcUs) AND 
IDIOPAtHIc DYsPLAsIA (IDUs) OF 
UNDEtErMINED sIGNIFIcANcE
A diagnostic challenge are patients who do not fulfil 
minimal diagnostic criteria for MDS but are suffering from 
persistent (> 6 months) cytopenia or exhibit unexplained 
dysplasia  without  marked  cytopenia.  In  these  patients, 
repeated BM investigations and an extensive search for 
an underlying disease are usually initiated. Repeated tests 
in the follow up may reveal an underlying hematologic or 
non-hematologic disease or imminent MDS. If this is not 
the case, a provisional diagnosis should be established: in 
those with marked and persistent cytopenia (hemoglobin 
<10 g/dL and/or neutrophils <1,000/µL and/or platelets 
<100,000/µL) but no evident dysplasia (<10% of cells in 
major BM lineages) the diagnosis Idiopathic Cytopenia 
of  Undetermined  (Uncertain)  Significance  (ICUS)  is 
established  [7,57].  In  those  patients  who  have  marked 
dysplasia (≥10% in at least one major lineage) with or 
without an MDS-related karyotype but no or only mild 
cytopenia, the term Idiopathic Dysplasia of Undetermined 
(Uncertain) Significance (IDUS) should be applied (Table 
4)  [57].  By  definition  the  presence  of  both  ICUS  and 
IDUS is exclusive since coexistence of these conditions 
is diagnostic and meets criteria for MDS [57]. Some of 
these IDUS patients progress to frank MDS over time, 
whereas others may progress to a myelodysplastic/
myeloproliferative neoplasm. All patients with ICUS and 
IDUS should have a hematologic follow-up in order to 
document or exclude evolution to MDS. One of the most 
important diagnostic investigations in patients with IDUS 
and ICUS is the histopathological examination of the BM. 
In fact, the diagnosis ICUS can only be established when 
the hematopathologist confirms the absence of dysplasia, 
and excludes all other BM disorders including aplastic 
anemia and hairy cell leukemia. For the same reason, 
the diagnosis IDUS is also dependent on the final report 
of the hematopathologist who has to exclude a number 
of  differential  diagnoses  and  can  confirm  multilineage 
dysplasia. The faculty also discussed minimal diagnostic 
criteria  for  IDUS,  and  concluded  that  the  presence  of 
dysplasia in at least two BM lineages would allow for a 
more proper diagnosis of IDUS than has been proposed 
before, where mild dysplasia in only one BM lineage 
might still be a questionable condition, not fulfilling the 
criteria of a clearly dysplastic myelopoiesis.
An important diagnostic approach in patients 
with  ICUS,  IDUS,  and  MDS,  is  fluorescence  in  situ 
hybridization (FISH) of BM interphase cells, especially 
when  conventional  chromosome  analysis  showed  a 
normal karyotype or yielded unclear results. In several 
of  these  patients,  FISH  may  reveal  the  presence  of  a 
small population of clonal cells carrying an MDS-related 
cytogenetic defect [57]. Sometimes, when recorded over 
time, the size of the clone (number of “FISH-positive” 
cells) may increase, BM function (i.e. the number of 
colony-forming progenitors) decreases, and MDS can then 
be diagnosed. Although IDUS may not be a rare condition, 
the number of well-documented cases is very low. Similar 
to patients with ICUS, patients with IDUS should have a 
hematologic follow up in order to document or exclude 
evolution to MDS. BM studies should be repeated when 
cytopenia develops or other signs for evolution to frank 
MDS  are  found.  However,  not  all  patients  with  ICUS 
or IDUS develop MDS even when recorded over many 
years.
cONcLUDING rEMArKs AND FUtUrE 
PErsPEctIVEs 
Although parameters, assays, and score systems 
have  improved  markedly  over  the  past  two  decades, 
appropriate diagnosis and optimal prognostication of MDS 
remains a challenge in clinical practice. A recommended 
approach  is  to  proceed  in  a  step  wise  fashion.  In  a 
first  step,  the  diagnosis  MDS  should  be  confirmed  by 
minimal diagnostic criteria. In a second step, the WHO 
classification  is  applied  to  define  the  disease  subtype. 
Important  prognostic  markers  which  should  always  be 
integrated in the report include the presence and grade 
of BM fibrosis and the AMA-CD34. Then, the IPSS or 
WPSS are applied for prognostication. Finally, therapy-
specific  scores  including  the  EPO-score,  co-morbidity 
score and transplant-score are applied in order to better 
decide what treatment options are best indicated for the 
given  patient.  For  patients  with  ICUS  and  IDUS,  the 
general recommendation is to manage the patient in the 
same way as patients who have low risk MDS. All these 
recommendations should facilitate the management and 
may improve the clinical outcomes in MDS.
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